AKEBIA THERAPEUTICS INC (AKBA) Stock Price & Overview
NASDAQ:AKBA • US00972D1054
The current stock price of AKBA is 1.27 USD. Today AKBA is up by 6.72%. In the past month the price decreased by -7.97%. In the past year, price decreased by -33.16%.
AKBA Key Statistics
- Market Cap
- 340.208M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.02
- Dividend Yield
- N/A
AKBA Stock Performance
AKBA Stock Chart
AKBA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to AKBA. When comparing the yearly performance of all stocks, AKBA is a bad performer in the overall market: 87.06% of all stocks are doing better.
AKBA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AKBA. There are concerns on the financial health of AKBA while its profitability can be described as average.
AKBA Earnings
On February 26, 2026 AKBA reported an EPS of -0.05 and a revenue of 57.62M. The company missed EPS expectations (-96.08% surprise) and beat revenue expectations (22.56% surprise).
AKBA Forecast & Estimates
11 analysts have analysed AKBA and the average price target is 4.69 USD. This implies a price increase of 269.45% is expected in the next year compared to the current price of 1.27.
For the next year, analysts expect an EPS growth of -295.25% and a revenue growth 2.87% for AKBA
AKBA Groups
Sector & Classification
AKBA Financial Highlights
Over the last trailing twelve months AKBA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 93.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.42% | ||
| ROE | -16.39% | ||
| Debt/Equity | 5.4 |
AKBA Ownership
AKBA Latest News, Press Relases and Analysis
AKBA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AKBA
Company Profile
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 194 full-time employees. The company went IPO on 2014-03-20. The firm's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.
Company Info
AKEBIA THERAPEUTICS INC
245 First Street
Cambridge MASSACHUSETTS 02142 US
CEO: John P. Butler
Employees: 194
Phone: 16178712098
AKEBIA THERAPEUTICS INC / AKBA FAQ
What does AKBA do?
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 194 full-time employees. The company went IPO on 2014-03-20. The firm's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.
What is the current price of AKBA stock?
The current stock price of AKBA is 1.27 USD. The price increased by 6.72% in the last trading session.
Does AKEBIA THERAPEUTICS INC pay dividends?
AKBA does not pay a dividend.
How is the ChartMill rating for AKEBIA THERAPEUTICS INC?
AKBA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about AKEBIA THERAPEUTICS INC (AKBA) stock?
11 analysts have analysed AKBA and the average price target is 4.69 USD. This implies a price increase of 269.45% is expected in the next year compared to the current price of 1.27.
What is the expected growth for AKBA stock?
The Revenue of AKEBIA THERAPEUTICS INC (AKBA) is expected to grow by 2.87% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is AKEBIA THERAPEUTICS INC worth?
AKEBIA THERAPEUTICS INC (AKBA) has a market capitalization of 340.21M USD. This makes AKBA a Small Cap stock.